Gefitinib, also known as Iressa, is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and a potential clinical anticancer drug, particularly with significant anti-tumor activity against non-small cell lung cancer (NSCLC) and ovarian cancer [114]. The gene discussed is EGFR; the disease is neoplasm.